Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
Hitomi Jo, Tatsuya Yoshida, Hidehito Horinouchi, et al.
Cancer Immunology Immunotherapy (2021) Vol. 71, Iss. 2, pp. 387-398
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Mortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis
Philip Bonomi, Jeffrey Crawford, Richard F. Dunne, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 4, pp. 1226-1239
Open Access | Times Cited: 9
Weight and Blood‐Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients
Steven Tran, Noah Forrest, Vijeeth Guggilla, et al.
Journal of Cachexia Sarcopenia and Muscle (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis
Taiki Hakozaki, Alexis Nolin-Lapalme, Masato Kogawa, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5405-5405
Open Access | Times Cited: 29
Cancer cachexia: biomarkers and the influence of age
Julia Geppert, Maria Rohm
Molecular Oncology (2024)
Open Access | Times Cited: 6
Exosomal IL-8 derived from Lung Cancer and Colon Cancer cells induced adipocyte atrophy via NF-κB signaling pathway
Hairong Xiong, Jiaxin Ye, Kairu Xie, et al.
Lipids in Health and Disease (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II
Sham S. Kakar, Vasa Vemuri, Mariusz Z. Ratajczak
Cells (2025) Vol. 14, Iss. 4, pp. 244-244
Open Access
Inflammation as a Therapeutic Target in Cancer Cachexia
Gerald H. Clamon, Margaret M. Byrne, Erin E. Talbert
Cancers (2022) Vol. 14, Iss. 21, pp. 5262-5262
Open Access | Times Cited: 16
Understanding cachexia and its impact on lung cancer and beyond
Meiting Yue, Zhen Qin, Liang Hu, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2024) Vol. 2, Iss. 2, pp. 95-105
Open Access | Times Cited: 3
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 4, pp. 1042-1051
Open Access | Times Cited: 3
Involvement of the gut microbiota in cancer cachexia
Brandon N. VanderVeen, Thomas D. Cardaci, Brooke M. Bullard, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 3, pp. C661-C670
Closed Access | Times Cited: 3
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer
Orhun Akdoğan, Betül Öğüt, Osman Sütçüoğlu, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Prevalence of and survival with cachexia among patients with cancer: A systematic review and meta-analysis
Tomoya Takaoka, Akinori Yaegashi, Daiki Watanabe
Advances in Nutrition (2024) Vol. 15, Iss. 9, pp. 100282-100282
Open Access | Times Cited: 3
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
Danilo Rocco, Luigi Della Gravara, Angela Ragone, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4684-4684
Open Access | Times Cited: 8
Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients
Haoqian Li, Butuo Li, Xiaoqing Wang, et al.
Nutrition (2024) Vol. 124, pp. 112462-112462
Open Access | Times Cited: 2
Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system
Zhenxing Tao, Zhiqin Chen, Yong Gao, et al.
Cancer Reports (2024) Vol. 7, Iss. 5
Open Access | Times Cited: 2
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Majd Issa, Joy Tang, Yizhen Guo, et al.
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 8, pp. 861-874
Open Access | Times Cited: 10
Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study
Yukinori Takenaka, Norihiko Takemoto, Tomoyuki Otsuka, et al.
Oral Oncology (2022) Vol. 132, pp. 106018-106018
Closed Access | Times Cited: 10
Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature
Jeffrey R. Proctor, Harvey Wong
Clinical and Translational Science (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients
Mayu Ohuchi, Shigehiro Yagishita, Hitomi Jo, et al.
Lung Cancer (2022) Vol. 173, pp. 35-42
Open Access | Times Cited: 8
Immunodiagnosis — the promise of personalized immunotherapy
R. Wang, Kairong Xiong, Zhimin Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer
Madeline MacDonald, Darin Poei, Alexis Leyba, et al.
Cancer Treatment and Research Communications (2023) Vol. 36, pp. 100752-100752
Open Access | Times Cited: 4
Exploring the multifaceted effects of Interleukin-1 in lung cancer: From tumor development to immune modulation
Mingbo Tang, Yipeng Yin, Wei Wang, et al.
Life Sciences (2024) Vol. 342, pp. 122539-122539
Open Access | Times Cited: 1
Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients
Yean Yu, Yan Li, Tianhui Huang, et al.
Aging (2024) Vol. 16, Iss. 6, pp. 5354-5369
Open Access | Times Cited: 1
Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis
Junfang Zhang, Xuan Tang, Wenbo Zhang, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 7, pp. 1618-1625
Closed Access | Times Cited: 1
Malnutrition and Erythropoietin Resistance among Patients with End-Stage Kidney Disease: Where Is the Perpetrator of Disaster?
Wiktoria Feret, Krzysztof Safranow, Ewa Kwiatkowska, et al.
Nutrients (2022) Vol. 14, Iss. 24, pp. 5318-5318
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top